Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease

Earlier this week at the Australia and New Zealand Cellular Therapy and Transplant Conference (ANZTCT), Dr Ashleigh Scott of Cynata Therapeutics presented their latest clinical progress: a Phase 2 randomised, double-blind, placebo-controlled trial of CYP-001 for high-risk acute graft-versus-host disease (HR-aGvHD). CYP-001, manufactured with its proprietary Cymerus® technology, delivers consistent, high-quality mesenchymal stem cells that can help restore immune balance and offer hope where options are limited.

Building on Phase 1 success, they have recorded an 87% overall response rate in steroid-resistant acute GvHD and a 60% two-year survival, with primary results expected in early 2026.

Connect with BioScience Managers to explore how we’re working with innovative biotech companies such as Cynata Therapeutics in delivering life-changing therapies.